Korean medical AI company Lunit is advancing its U.S. expansion by submitting its breast cancer risk prediction solution, Lunit INSIGHT...
breast
Women who’ve been treated for hormone-sensitive breast cancer often face five to 10 years of endocrine therapy to lower the...
